IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance.
about
Personalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicineGene expression and thiopurine metabolite profiling in inflammatory bowel disease - novel clues to drug targets and disease mechanisms?IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations.Pharmacogenomics in the treatment of inflammatory bowel disease.Thiopurines in Crohn's disease, is there something new?Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia.Current relevance of pharmacogenetics in immunomodulation treatment for Crohn's disease.Allopurinol enhanced thiopurine treatment for inflammatory bowel disease: safety considerations and guidelines for use.Update on thiopurine pharmacogenetics in inflammatory bowel disease.New challenges and promises in solid organ transplantation pharmacogenetics: the genetic variability of proteins involved in the pharmacodynamics of immunosuppressive drugs.Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients.Allopurinol-thiopurine combination therapy in inflammatory bowel disease: are there genetic clues to this puzzle?Optimizing thiopurine therapy: more weight to the metabolite argument.Assessment of mercaptopurine (6MP) metabolites and 6MP metabolic key-enzymes in childhood acute lymphoblastic leukemia.High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment.Institutional profile: The Carney Centre for Pharmacogenomics: a New Zealand focus for personalized medicine research.Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and MetabolismRevisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring
P2860
Q28082746-D2F3F565-66EB-43B4-B1B4-166E3D309071Q28486322-0B3B5B5C-E64E-4A73-AC9A-8768D49A8F01Q36535994-514AE22F-E298-4012-BE9F-8D6FEC1C31F4Q37710516-0612CD84-0EFB-49BC-A5BC-B7A2AC234292Q37797517-FE4B8978-1CA9-4E77-86AE-E2A5F100F1B8Q37994062-6474D691-B229-4DC1-B772-1C4F5E3E19B3Q38022258-A935BC91-7ECF-452F-8D77-C6AF861E3655Q38179509-211E791F-0671-43DA-96B1-2E2DD8590B0DQ38525578-499588B4-2710-4A13-B7DF-721C7775C444Q38707932-FC8F7C67-26C8-43AD-97E0-597E099A1C41Q39047242-82F29269-3355-4285-BE46-18534C670603Q42788962-CC7B460A-BD43-4C3E-B1C4-3A8E2A59E5DBQ42873636-5EECC6E0-61A5-4EBF-8671-C68A95155542Q46793120-279C20F0-DE9F-4E36-BD75-035A31DB2DB6Q51385316-4B8F55D7-B0DF-4C9C-990F-3F9E76247BA4Q53128897-D2B2B617-42AA-4D2E-B3DB-5A6F4E26BB76Q57175017-4F48B52D-9C44-4CC6-AA75-B6808FFFE35CQ57817595-C91FCFF8-5F0D-4D0E-A7EB-7D4143A74DC8
P2860
IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance.
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance.
@ast
IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance.
@en
IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance.
@nl
type
label
IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance.
@ast
IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance.
@en
IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance.
@nl
prefLabel
IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance.
@ast
IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance.
@en
IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance.
@nl
P2860
P50
P356
P1476
IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance
@en
P2093
Roberts RL
P2860
P2888
P304
P356
10.1038/SJ.TPJ.6500421
P577
2006-10-17T00:00:00Z
P5875
P6179
1019130582